title: [The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell].
abstract: OBJECTIVE
  This study was designed to prove simultaneously blocking both EGFR and COX-2-mediated pathways may be an efficient means of inhibiting cancer cell growth in NPC.
  
  
  METHODS
  A combination of tarceva (EGFR-selective tyrosine kinase inhibitors) with celecoxib (Cox-2 inhibitor) was studied on its effects on cell growth, cell cycle progression, apoptosis and protein expression in CNE-2 cell lines by cell growth assay, flow cytometric analysis assay and Western blotting.
  
  
  RESULTS
  (1) The inhibition rate of cell growth was higher in the group treated with a combination of two agents than that the sum of rates of the two groups treated with only one agent (P < 0.05). (2) The combination of tarceva with celecoxib significantly induced G1 arrest (P < 0.05), but did not increase apoptosis rate (P > 0.05). (3) The group of combination showed less expressions of p-EGFR and COX-2 than any other group.
  
  
  CONCLUSIONS
  Simultaneously blocking EGFR and COX-2 mediated pathways would significantly inhibit the growth of CNE-2 cell line, increase G1 arrest and reduce the expression levels of p-EGFR and COX-2.
authors.affiliation: Department of Otorhinolaryngology, Affiliated Xiangya Hospital, Central South University, Changsha, 410008, China.
authors.forename: Shi-sheng
authors.initials: SS
authors.lastname: Li
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Xu
authors.forename: Li
authors.initials: L
authors.lastname: Xie
authors.forename: Yuanzheng
authors.initials: Y
authors.lastname: Qiu
authors.forename: Xin
authors.initials: X
authors.lastname: Shu
authors.forename: Yongquan
authors.initials: Y
authors.lastname: Tian
mesh_terms: D017209:Apoptosis; D000068579:Celecoxib; D002455:Cell Division; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology*; D015398:Signal Transduction; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D011720:Pyrazoles; D011799:Quinazolines; D013449:Sulfonamides; D000069347:Erlotinib Hydrochloride; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068579:Celecoxib